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Progress of mesenchymal stem cell therapy for neural and
retinal diseases
Tsz Kin Ng, Veronica R Fortino, Daniel Pelaez, Herman S Cheung
without any genetic modification or reprogramming. In
addition, the extraordinary immunomodulatory properties of MSCs enable autologous and heterologous
transplantation. These qualities heighten the clinical applicability of MSCs when dealing with the pathologies of
CNS disorders. Here, we summarize the latest progress
of MSC experimental research as well as human clinical
trials for neural and retinal diseases. This review article
will focus on multiple sclerosis, spinal cord injury, autism, glaucoma, retinitis pigmentosa and age-related
macular degeneration.
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Core tip: Central nervous system (CNS) disorders are
the most challenging and difficult for functional repair.
Neurons are still diminishing in many patients despite
surgical and medical interventions. Stem cell therapy
has been proposed as a viable option. Mesenchymal
stem cell (MSC) is a widely-studied human adult stem
cell population. MSCs can be conveniently obtained
from different accessible tissues. MSCs have high proliferative and differentiation abilities, providing an inexhaustible source of neurons and glia. MSCs also show
neuroprotective effects and possess extraordinary immunomodulatory properties. These qualities heighten
the clinical applicability of MSCs when dealing with the
pathologies of CNS disorders.

Abstract
Complex circuitry and limited regenerative power make
central nervous system (CNS) disorders the most challenging and difficult for functional repair. With elusive
disease mechanisms, traditional surgical and medical
interventions merely slow down the progression of the
neurodegenerative diseases. However, the number of
neurons still diminishes in many patients. Recently,
stem cell therapy has been proposed as a viable option. Mesenchymal stem cells (MSCs), a widely-studied
human adult stem cell population, have been discovered for more than 20 years. MSCs have been found all
over the body and can be conveniently obtained from
different accessible tissues: bone marrow, blood, and
adipose and dental tissue. MSCs have high proliferative
and differentiation abilities, providing an inexhaustible
source of neurons and glia for cell replacement therapy. Moreover, MSCs also show neuroprotective effects
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lineage, including neuron-like cells. MSCs are not only
able to differentiate into neurons for cell replacement
therapy, they also exert paracrine effects by modulating
the plasticity of damaged host tissues, secreting neurotrophic and survival-promoting growth factors, restoring synaptic transmitter release, integrating into existing
neural and synaptic networks, and re-establishing functional afferent and efferent connections[8]. These paracrine activities have not been reported in ESCs or iPSCs.
Moreover, MSCs possess strong immunosuppressive
properties and inhibit the release of pro-inflammatory
cytokines[9]. This allows autologous, as well as, allogeneic
transplantation of MSCs without the need of pharmacological immunosuppression. Furthermore, MSCs can
be transplanted directly without genetic modification or
pre-treatments, and are able to migrate to the tissue injury sites[10]. In addition, there is no teratoma formation
concern after transplantation[11], and no moral objection
or ethical controversies involved in their attainment[12].
These advantageous properties, as well as the expansion
potential of MSCs initiate the idea of clinical applications
of MSCs to treat different human diseases, especially
CNS disorders. Currently, over 100 MSC clinical trials for
different diseases have been listed by the United States
National Institutes of Health trial database (www.clinicaltrials.gov), indicating that MSC therapy is a popular
trend for the field of regenerative medicine in the years
to come.
This review article provides an update on the progress
of MSC experimental research as well as human clinical
trials for neural and retinal diseases with emphasis on
multiple sclerosis, spinal cord injury, autism, glaucoma,
retinitis pigmentosa and age-related macular degeneration.

STEM CELL THERAPY AND
MESENCHYMAL STEM CELLS
Stem cells are undifferentiated cells defined by their ability to self-renew and differentiate into mature cells. Stem
cells are attractive because they are highly proliferative,
implying that an inexhaustible number of mature cells
can be generated from a given stem cell source. On this
basis, cell replacement therapy has been proposed in recent years as a viable alternative for various pathologies.
Cell replacement therapy hypothesizes that new retinal
cells could be generated from stem cells so as to substitute the damaged cells in the diseased retina. This theory
is mainly established from embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs). In addition to
cell replacement function, stem cells could have another
protective effect, the paracrine effect. The paracrine effects of stem cells are believed to modulate the microenvironment of the diseased tissues so as to protect the
injured cells, promote survival and activate any available
endogenous repair mechanisms. This latter observation
applies mainly to the transplantation of adult stem cells.
Adult stem cells are defined as the stem cells found in
fully developed tissues. The function of adult stem cells
is the maintenance of adult tissue specificity by homeostatic cell replacement and tissue regeneration[1]. Adult
stem cells are presumed quiescent within adult tissues,
but divide infrequently to maintain their own niche by
generating a stem cell clone and a transiently-amplifying
cell. The transiently-amplifying cells will undergo a limited number of cell divisions before terminal differentiation into mature functional tissue cells. The existence of
adult stem cells has been reported in multiple organs;
these include: brain, heart, skin, intestine, testis, muscle
and blood, among others.
Mesenchymal stem cells (MSCs), also called marrow
stromal cells, are an adult stem cell population of stromal progenitor cells of mesodermal origin[2]. MSCs were
originally identified in the bone marrow, representing
0.001%-0.01% of the bone marrow population. MSCs
can also be found in other systems all over the body, such
as adipose tissue, liver, umbilical cord, central nervous
system (CNS) and dental tissues[3]. According to the International Society of Cellular Therapy[4], the minimal
criteria to define MSCs are: (1) grown in adherence to
plastic surface of dishes when maintained in standard
culture conditions; (2) positive expression of cytospecific cell surface markers (CD105, CD90 and CD73) and
negative expression of other cell surface markers (CD45,
CD34, CD14 and CD11b); and (3) capacity to differentiate into mesenchymal lineages, under appropriate in vitro
conditions. In addition to the expression of the three
cell surface markers, MSCs also express CD29, CD44,
CD146 and STRO-1[5].
The function of MSCs is to differentiate into osteocytes, chondrocytes, myoblasts and adipocytes[6,7]. An
increasing number of studies, however, report that MSCs
are capable of giving rise to cells of an entirely distinct
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MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is an immune-mediated neurodegenerative disorder of the CNS, affecting over 1.3 million
people worldwide. The histopathological hallmark of
MS is the formation of an inflammatory plaque, which
originates from a breach in the integrity of the bloodbrain barrier[13]. The histologic features of lesions in MS
include: lymphocyte infiltration, loss of oligodendrocytes, demyelination, and widespread axonal damage[14].
Myelin-reactive T cells, which secrete interferon- and
interleukins, have been suggested to be responsible for
the inflammatory demyelination seen in MS[15]. Currently,
there are three treatment options approved by the Food
and Drug Administration (FDA) for MS: administration
of interferon beta, glatiramer acetate, or mitoxantrone[16].
However, there is still no medical cure for MS.
Experimental autoimmune encephalomyelitis (EAE),
the best known and most commonly used model for MS,
mechanistically defines the immune processes responsible
for the clinical manifestations and development of MS[17].
This animal model provides insight for the application
of immunotherapy to treat MS[18]. MSCs have been pro-
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SCI therapeutic strategies can vary greatly[26]. Most SCI
patients are in the chronic phase, characterized by ongoing demyelination, local inflammation and apoptosis, decreased number of activated macrophages, and formation
of glial scar and pseudocysts[27]. The present standard
treatment for SCI patients is surgical intervention, high
doses of methylprednisolone, and symptomatic therapy
followed by rehabilitation [28]. New neuroregenerative
strategies will be focused on neuroprotection and axonal
regeneration in a permissive environment.
Cellular therapy aims to reconstruct the spinal cord
through cellular replacement, glial scar remodeling, axonal guidance, and filling of formed syringomyelia[29]. In
vivo administration of MSCs in different SCI animal models showed functional recovery including: increased motor activity and sensation in the paralyzed limbs, reduced
cavity formation in the spinal cord, and axonal sprouting
through the glial scar[30,31]. The objective of MSC application is to ameliorate the consequences of secondary injury by preserving the host nerve cells, rather than replacing them[32].
Comparable to MS studies, there are 11 registered
clinical trials using MSCs for SCI treatment (Table 1),
among which two studies (one from Egypt and one from
South Korea) have been completed. The Korean study
investigated the safety of single intravenous infusion of
autologous adipose tissue-derived MSCs (4 × 108 cells) in
8 male patients with chronic SCI (NCT01274975; http://
clinicaltrials.gov/)[33]. No adverse events were observed.
Although one patient showed improvement in the American Spinal Injury Association (ASIA) scale from grade
A (No sensory or motor function is preserved in sacral
segments S4-S5) to grade C (Motor function is preserved
below the neurologic level, and most key muscles below
the neurologic level have muscle grade less than 3) and
three patients showed motor score improvement, this
phase I clinical trial might not have the statistical power
to conclude on the efficacy of treatment effect with adipose tissue-derived MSCs on SCI. The study conducted
in Egypt (NCT00816803; http://clinicaltrials.gov/), is
a Phase-1/2 clinical trial applying bone marrow-derived
MSCs at the injury site of chromic SCI patients. However, no results of this study have been released. Finally,
there are two Phase-3 clinical trials taking place in China
(NCT01873547; http://clinicaltrials.gov/) and Korea
(NCT01676441; http://clinicaltrials.gov/). The study
in China plans to use umbilical cord MSCs to treat 100
chronic SCI patients compared to the rehabilitation-only
group and no stem cell and rehabilitation group, whereas
the study in Korea was designed to transplant bone marrow-derived MSCs to treat 32 chronic SCI patients. For
other ongoing clinical trials in SCI, the approaches are
mainly intrathecal transplantation of bone marrow-derived MSCs and adipose tissue-derived MSCs in chronic
SCI patients.

posed as a treatment for autoimmune diseases, including MS, because of their immunosuppressive properties
and neural repair function[19]. Transplantation of human
MSCs into animals with ongoing EAE results in rapid
and sustained functional recovery due to a reduced number of inflammatory myelin-specific Th1 cells and astrocytes as well as an increased number of inflammatoryinhibiting Th2 cells, oligodendrocytes and neurons[20].
This functional benefit is a critical stepping-stone towards
effective MSC therapies in MS patients.
Among all of the CNS disorders, MS has the highest number of registered clinical trials. Altogether there
are 14 registered clinical trials for MS (Table 1), and two
of them have been published. The study from Israel is a
phase-1/2 open safety clinical trial to evaluate the feasibility, safety and immunological effects of intrathecal and
intravenous administration of autologous MSCs in 15 MS
patients (NCT00781872; http://clinicaltrials.gov/)[21]. No
major adverse effects have been reported in this study,
and the mean Expanded Disability Status Scale (EDSS)
improved from 6.7 to 5.9 (EDSS steps 1.0 to 4.5: MS
patients are fully ambulatory, whereas EDSS steps 5.0 to
9.5: MS patients are impaired to ambulation). Moreover,
magnetic resonance imaging visualized the MSCs in the
occipital horns of the ventricles, indicating migration of
the cells. In addition, the proportion of CD4+/CD25+
regulatory T cells increased, whereas the proliferative
responses of lymphocytes decreased. The mesenchymal
stem cells in the multiple sclerosis trial (MSCIMS) originated in the United Kingdom, is an open-label phase 2a
proof-of-concept study of autologous MSCs in secondary progressive MS (NCT00395200; http://clinicaltrials.
gov/)[22,23]. In this study, 10 patients received intravenous
infusion of autologous bone marrow-derived MSCs (1.6
× 106 cells per kg body weight). The “sentinel lesion approach” assessing the anterior visual pathway was used
to measure the efficacy of treatment. Results show that
treatment improved visual acuity, visual evoked response
latency, and increased the optic nerve area of the recipients. No serious adverse events were identified. For other
clinical trials, mainly autologous MSCs have been used,
although one study from China uses umbilical cord MSCs
(NCT01364246; http://clinicaltrials.gov/). Interestingly,
an open-label phase I clinical trial from New York was
designed to evaluate autologous MSC-derived neural progenitor cells in progressive MS patients (NCT01933802;
http://clinicaltrials.gov/) even though neural stem cells
from EAE animals mainly develop astrocytes rather than
oligodendrocytes, or oligodendrocyte precursor cells and
neurons[20].

SPINAL CORD INJURY
Spinal cord injury (SCI) is the most devastating and traumatic disorder among CNS conditions[24]. The worldwide
frequency of SCI is about 40 cases per million individuals[25]. SCI can be caused by traffic accidents, violent assaults, falls, sport and other traumatic events. Depending
on the injury location, extent, phases and time frames,
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Autism belongs to a spectrum of heterogeneous neuro-
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Table 1 Registered clinical trials on mesenchymal stem cells for neural diseases
Identifier

Country

Status

Study

Phase of
trial

NCT01377870

Iran

Recruiting

Phase 1/2

30

2013

Multiple
sclerosis

NCT01895439

Jordan

Recruiting

Phase 1/2

30

2014

NCT01883661

India

Not yet
recruiting
Completed

Evaluation of autologous mesenchymal stem cell
transplantation (effects and side effects) in multiple
sclerosis
Safety and efficacy study of autologous bone marrow
mesenchymal stem cells in multiple sclerosis
Safety and efficacy of MSCs in MS

Phase 1/2

15

2015

MSCIMS

Phase 1/2

10

2010

Recruiting

MESEMS

Phase 1/2

20

2014

Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis

NCT00395200

United
Kingdom
NCT01854957
Italy

Estimated number Estimated
of patients
trial end

Disease

NCT01730547

Sweden

Recruiting

Mesenchymal stem cells for multiple sclerosis

Phase 1/2

15

2015

NCT01364246

China

Recruiting

Phase 1/2

20

2014

NCT01056471

Spain

Unknown

Phase 1/2

30

2012

Multiple
sclerosis

NCT01228266

Spain

Active, not
recruiting
Active, not
recruiting
Not yet
recruiting
Recruiting

Safety and efficacy of umbilical cord
mesenchymal stem cell therapy for patients
with progressive multiple sclerosis and neuromyelitis
optica
Autologous mesenchymal stem cells from adipose
tissue in patients with secondary progressive multiple
sclerosis (CMM/EM/2008)
Mesenchymal stem cell transplantation in MS (CMMEM)
Autologous MSC transplantation in MS

Phase 2

16

2013

Phase 1

24

2014

Intrathecal administration of autologous MSC-NP in
patients with multiple sclerosis
STREAMS

Phase 1

20

2016

Phase 1/2

13

2015

Mesenchymal cells from autologous bone marrow,
Phase 1/2
administered intravenously in patients diagnosed with
multiple sclerosis
MSCs for the treatment of MS
Phase 1/2

30

2014

Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis
Multiple
sclerosis

20

2009

Autologous mesenchymal stem cells in spinal cord
injury (SCI) patients (MSC-SCI)
Mesenchymal stem cells transplantation to patients
with spinal cord injury (MSC)
Safety and efficacy of autologous mesenchymal stem
cells in chronic spinal cord injury
Safety and effect of adipose tissue derived
mesenchymal stem cell implantation in patients with
spinal cord injury
Transfer of bone marrow derived stem cells for the
treatment of spinal cord injury
Autologous adipose derived mscs transplantation in
patient with spinal cord injury
Intrathecal transplantation of autologous
adipose tissue derived msc in the patients with spinal
cord injury
Difference between rehabilitation therapy and stem
cells transplantation in patients with spinal cord injury
in China
Different efficacy between rehabilitation therapy and
stem cells transplantation in patients with SCI in China
(SCI-Ⅲ)
Autologous bone marrow stem cell transplantation in
patients with spinal cord injury
Cell transplant in spinal cord injury patients

Phase 2

30

2014

Phase 1/2

20

2014

Phase 2/3

32

2014

Phase 1/2

15

2014

Phase 1

10

2013

Phase 1

8

2010

Phase 1

15

2013

Phase 2

60

2012

Spinal cord
injury

Phase 3

300

2014

Spinal cord
injury

Phase 1

20

2013

Phase 1/2

80

2008

Safety and efficacy of stem cell therapy in patients with Phase 1/2
autism

37

2011

Spinal cord
injury
Spinal cord
injury
Autism

NCT00813969

United
States
NCT01933802 United
States
NCT01606215 United
Kingdom
NCT01745783
Spain

Recruiting

NCT00781872

Israel

Unknown

NCT01694927

Chile

NCT01446640

China

Enrolling by
invitation
Recruiting

NCT01676441

South
Korea
South
Korea

Recruiting

United
States
South
Korea
South
Korea

Active, not
recruiting
Completed

NCT01393977

China

Unknown

NCT01873547

China

Recruiting

NCT01325103

Brazil

Unknown

NCT00816803

Egypt

Completed

NCT01343511

China

Completed

NCT01769872

NCT01162915
NCT01274975
NCT01624779

Recruiting

Recruiting

Multiple
sclerosis
Spinal cord
injury
Spinal cord
injury
Spinal cord
injury
Spinal cord
injury
Spinal cord
injury
Spinal cord
injury
Spinal cord
injury

Information obtained from http://clinicaltrials.gov/. MSCs: Mesenchymal stem cells; MS: Multiple sclerosis; MSCIMS: Mesenchymal Stem Cells in
Multiple Sclerosis; MESEMS: MEsenchymal StEm Cells for Multiple Sclerosis; MSC-NP: Mesenchymal Stem Cell-derived Neural Progenitors; STREAMS:
Stem Cells in Rapidly Evolving Active Multiple Sclerosis.
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developmental disorders[34]. It is characterized by abnormalities in social interaction, impaired verbal and nonverbal communication, and repetitive, obsessive behavior[35].
According to the Centers for Disease Control, the prevalence of autism hovers around 60 in every 10000 children[36]. Even though there is no defined gold standard
approach, current interventions for autism can be divided
into behavioral, nutritional and pharmacological[37]. Medical interventions aim to ameliorate the neuropsychiatric
disorders associated with autism. The medications include
selective serotonin reuptake inhibitors (SSRI’s), typical
and atypical anti-psychotic drugs, psycho-stimulants, α-2
agonists, β blockers, lithium, anti-convulsant mood stabilizers and anti-depressants[38-40]. Unfortunately, autism is
still not treatable.
The pathogenic mechanism of autism is not clearly
understood and remains elusive. Nevertheless, two
pathologies are commonly found within the autism patients: the first observation is an impaired central nervous system circulation and hypoperfusion to the brain,
whereas the second observation is systemic T cell and
B cell abnormalities as well as active neuroinflammatory
processes in the brain[41]. Based on the immunomodulatory properties of MSCs, therapies employing MSCs
have been proposed to target the immune deregulation
observed in autism. Basically, it is believed that MSCs are
able to inhibit the release of pro-inflammatory cytokines
and have strong immunosuppressive activity[42]. This not
only allows for autologous transplantation, but also heterologous transplantation without the requirement of
pharmacological immunosuppression[43].
Currently, there is only one registered human clinical
trial using MSCs to treat autism (NCT01343511; http://
www.clinicaltrials.gov/; Table 1). This study aimed to test
the safety and efficacy of human umbilical cord MSCs
and human cord blood mononuclear cell transplantation
in Chinese patients with autism[44]. Outcomes from this
study assuaged the safety concerns in using MSCs and
mononuclear cells for transplantation in autism patients,
and no severe adverse effects were observed. In addition, results also showed that combined transplantation
of MSCs and mononuclear cells (combination group)
had better therapeutic effects than transplantation of
mononuclear cells alone (CBMNC group) in terms of
the Childhood Autism Rating Scale (CARS) total score
(combination group: 28.00 ± 6.18; CBMNC group: 37.14
± 10.15; CARS total score > 30 means the child is considered to be autistic), Clinical Global Impression (CGI)
scale (combination group: 88% much improved or higher; CBMNC group: 49% much improved or higher) and
the Aberrant Behavior Checklist (ABC) total score (combination group: 36.78 ± 16.95; CBMNC group: 58.36 ±
31.73; a high score indicates greater severity while a low
score indicates a milder degree of difficulty).

neuropathies. It is characterized by a slow progressive
degeneration of retinal ganglion cells (RGCs) and their
axons, which results in visual field defects[45]. Glaucoma
is the leading cause of irreversible blindness, affecting
more than 60 million people worldwide[46]. Traditional
and current treatments for glaucoma are based on surgical or medical interventions to slow disease progression
and limit visual loss[47]. However, in many patients, the
numbers of RGCs still diminish, and glaucoma cannot be
completely cured.
The molecular basis of glaucoma is complex. The
pathophysiological mechanisms leading to RGC degeneration in glaucoma include a complex interaction between
primary axonal injury, neurotrophic factor deprivation,
ischemia, oxidative stress, mitochondrial dysfunction
and inflammation[48]. New therapies aim to supplement
neurotrophic factors, such as brain-derived neurotrophic
factor (BDNF), ciliary neurotrophic factor (CNTF), glial
cell line-derived neurotrophic factor (GDNF) and nerve
growth factor (NGF)[49]. However, repeated injections are
needed to achieve an observable effect[50]. To avoid multiple injections, cell-based delivery of neurotrophic factors was proposed. A phase-I clinical trial for glaucoma
(NCT01408472; http://clinicaltrials.gov/) using genetically modified CNTF-secreting retinal pigment epithelial
cells (NT-501 CNTF implant) has already been launchedthe outcomes have not been reported yet. Since MSCs
can produce neurotrophic factors, including BDNF,
CNTF, GDNF and basic fibroblast growth factor (bFGF),
without the requirement of genetic modification, MSC
transplantation has been suggested as a potential reservoir for neurotrophic factor secretion[51]. Bone marrowderived MSC transplantation increases RGC survival in a
model of transient ischemia followed by reperfusion[52],
and reduces RGC loss in ocular hypertension models[53,54].
Similarly, transplantation of human umbilical cord blood
MSCs promotes RGC survival in an optic nerve crush
model even after 7 d of injury[55]. In addition, intracranial
human umbilical cord blood MSC transplantation at the
site of optic tract transaction also protects RGCs and induces axonal regeneration[56]. The neuroprotective effect
of MSCs on RGC survival has clearly been proven, and
the first clinical trial using bone marrow-derived MSCs
on glaucoma in Florida (Stem Cell Ophthalmology Treatment Study (SCOTS)) has just started in August 2013
(NCT01920867; http://clinicaltrials.gov/; Table 2). This
study will be complete in 2017.

RETINITIS PIGMENTOSA AND AGERELATED MACULAR DEGENERATION
Retinitis pigmentosa (RP) is characterized by a classic pattern of difficulties in dark adaptation and night
blindness in adolescence, loss of mid-peripheral visual
field in young adulthood and central vision later in life.
These are due to the severe attenuation of rod and cone
photoreceptors[57]. RP is one of the hereditary degenerative diseases, affecting 1 in 4000 individuals. Age-related

GLAUCOMA
Glaucoma is a group of chronic, degenerative optic
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Table 2 Registered clinical trials on mesenchymal stem cells for retinal diseases
Identifier

Country

Status

Study

Phase of Estimated number of Estimated trial
trial
patients
end

NCT01531348 Thailand Enrolling by Feasibility and safety of adult human Phase 1
invitation bone marrow-derived mesenchymal
stem cells by intravitreal injection in
patients with retinitis pigmentosa
NCT01914913
India
Not yet
Clinical study to evaluate safety and Phase
recruiting efficacy of stem cell therapy in retinitis
1/2
pigmentosa
NCT01920867 United Recruiting
Stem cell ophthalmology treatment
States
study

Disease

10

2014

Retinitis pigmentosa

15

2015

Retinitis pigmentosa

300

2017

Glaucoma, retinitis
pigmentosa, age-related
macular degeneration

Information obtained from http://clinicaltrials.gov/.

macular degeneration (AMD) is the leading cause of irreversible blindness in people aged 50 years or above in
the developed world[58]. It influences the central portion
of the retina (the macula). Early AMD is characterized by
drusen (pale yellowish lesions), or by hyperpigmentation
and hypopigmentation of retinal pigment epithelium in
the macula. Late AMD is divided into the “non-exudative”
and “exudative” forms. The non-exudative form (geographic atrophy) starts with a sharply demarcated round
or oval hypopigmented spot in which large choroidal vessels are visible, whereas the exudative form, characterized
by choroidal neovascularization, is the detachment of the
neuroretina or RPE from Bruch’s membrane by serous
or hemorrhagic fluid[59,60].
Both RP and AMD involve photoreceptor cell death.
MSC research studies targeting this common pathology
can be divided into two categories: first, cell replacementbased studies aim to generate photoreceptor cells from
different sources of MSCs. MSCs from the trabecular
meshwork as well as the conjunctiva have been used to
produce photoreceptor-like cells in vitro[61,62]. Interestingly,
subretinal injection of MSCs has also been reported to
induce differentiation into photoreceptor cells in a sodium iodate-induced retinal degeneration rat model[63].
Second, studies based on paracrine effects hypothesize
that MSCs can secrete neurotrophic factors to protect
against photoreceptor degeneration in different animal
models. Transplantation of bone marrow-derived MSCs
can rescue photoreceptor cells of the dystrophic retina
in the rhodopsin knockout mouse model[64]. Moreover,
intravenous injection of bone marrow-derived MSCs rescue photoreceptor cells as well as visual function in the
Royal College of Surgeons rat model[65]. For AMD, beside
photoreceptor cell loss, retinal pigment epithelial (RPE)
cells are also affected. Adipose tissue-derived MSCs can
be induced to an RPE phenotype[66]. In addition, adipose
tissue-derived MSCs rescue mitomycin C-treated RPE
cell lines (ARPE19) from death in culture[67]. Furthermore, subretinal injected MSCs adopt RPE morphology
and preserve the retinal layer integrity in the sodium
iodate-induced retinal degeneration rat model[68].
To date, there are three ongoing registered clinical
trials using MSCs on RP (Table 2). The first clinical trial

WJSC|www.wjgnet.com

aims to determine the feasibility and safety of human
adult bone marrow-derived MSCs by intravitreal injection
in patients with RP in Thailand (NCT01531348; http://
clinicaltrials.gov/). The second clinical trial is the Stem
Cell Ophthalmology Treatment Study (SCOTS) in Florida (NCT01920867; http://clinicaltrials.gov/) proposed to
use autologous bone marrow-derived MSCs by different
means of injection (retrobulbar, subtenon, intravitreal,
intraocular, subretinal and intravenous). The third clinical
trial is a Phase-1/2 open labeled study done in India to
evaluate the safety and efficacy of bone marrow-derived
MSCs in RP (NCT01914913; http://clinicaltrials.gov/).
For AMD, there is only one registered clinical trial using bone marrow-derived MSCs (Table 2), the Stem Cell
Ophthalmology Treatment Study (SCOTS) in Florida
(NCT01920867; http://clinicaltrials.gov/). Results from
these studies have not been reported yet.

CONCLUSION
MSCs have been discovered for more than 20 years[69],
and have been found all over the body. MSCs can be conveniently obtained from different accessible tissues: bone
marrow, blood, and adipose and dental tissue. They can
also be easily expanded in standard culture conditions. In
addition to the above mentioned characteristics, MSCs
demonstrate neuroprotective effects, immunomodulatory
properties and self-migratory activity, making them an
attractive therapeutic tool. In recent years, MSC research
has already begun the transition from preclinical experiments to human clinical trials. There are currently more
than 60 MSC clinical trials dealing with CNS disorders
and three clinical trials on retinal diseases. Although
transient rash, self-limiting bacterial infections or fever
might occur in some patients after MSC transplantation,
serious adverse events have never been observed. This
can foresee that MSC transplantation will become routine
clinical practice for disease treatment in the near future.
However, there are critical challenges still needed to be
conquered before MSC therapy can be adopted in daily
clinical practice. These include: (1) poor MSC retention
in vivo; (2) poor MSC engraftment, viability and function
in vivo; (3) unclear mechanisms of action; and (4) lack
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of standardized trials[70]. Moreover, few studies showed
the contradictory results of MSC immunomodulatory
properties. This might be explained by the heterogeneous
MSC population. TLR4-primed human MSCs (MSC1)
mostly secrete pro-inflammatory cytokines (IL-6, IL-8)
while TLR3-primed human MSCs (MSC2) express mostly immunosuppressive mediators (IL-10, IDO, TSG-6)[71].
Addition of fewer MSCs (10-1000) would led to a less
consistent suppression or a marked lymphocyte proliferation in culture, whereas addition of 10000-40000 MSCs
have an inhibitory effect[72]. Besides, there are uncertainties that must be answered. What is the optimal cell number for transplantation? Which MSC types are optimal
for regenerative medicine? When is the optimal stage to
receive MSC therapy? Which transplantation route is suitable for each individual CNS disorder? Further research
is needed to understand the mechanisms elicited by stem
cells in regenerating damaged tissues after transplantation.
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